Evidence map›Paper›PMID 42504935›Full record

ArticleClinical pharmacology and therapeutics2026

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome-Wide Association Studies in Individuals With Type 2 Diabetes.

Joseph H Breeyear, John S House, Mark Kvale, Stella Nam, Farida S Akhtari, Hetal S Shah, Monique M Hedderson, Kathleen M Giacomini, Josyf C Mychaleckyj, Alessandro Doria and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Joseph H BreeyearBiostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.ORCID 0000-0002-6179-0515
John S HouseBiostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.ORCID 0000-0002-8447-7871
Mark KvaleDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.ORCID 0000-0003-0984-4878
Stella NamCenter for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Farida S AkhtariBiostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.
Hetal S ShahJoslin Diabetes Center and Harvard Medical School, Boston, Massachusetts, USA.
Monique M HeddersonDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.ORCID 0000-0001-8041-5430
Josyf C MychaleckyjCenter for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0003-2595-0005
Alessandro DoriaJoslin Diabetes Center and Harvard Medical School, Boston, Massachusetts, USA.
Michael J WagnerCenter for Pharmacogenomics and Individualized Therapy, UNC, Chapel Hill, North Carolina, USA.
Josephine H LiCenter for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-2314-0914
Sook Wah YeeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.ORCID 0000-0001-8121-8746
John B BuseDivision of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Richard P WoychikOffice of the Director, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.
Daniel M RotroffDepartment of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio, USA.
Alison A Motsinger-ReifBiostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.ORCID 0000-0003-1346-2493

Funding

PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KWOK, PUI-YAN · 2010 to 2014
$16.3M
Equipment Supplement for Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3R01GM117163 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLOREZ, JOSE CARLOS, HEDDERSON, MONIQUE MARIE · 2015 to 2023
$5.5M
Genetic modifiers of the effect of intensive glycemic control on CVD riskR01HL110400 · NHLBI · JOSLIN DIABETES CENTER · PI DORIA, ALESSANDRO · 2011 to 2014
$3.8M
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD TrialR01HL110380 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, WAGNER, MICHAEL JAY · 2012 to 2015
$2.4M
Elucidating the pharmacogenetics of the response to GLP-1 receptor agonists for type 2 diabetesK23DK131345 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Josephine H Li · 2022 to 2026
$953k
NHLBI NIH HHS GM117163NHLBI NIH HHS GM61390NHLBI NIH HHS R01 HL110380NHLBI NIH HHS R01 HL110380-04NHLBI NIH HHS R01 HL110400NIDDK NIH HHS K23 DK131345NIEHS NIH HHSNIGMS NIH HHS R01 GM117163NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U19 GM061390Novo Nordisk
6 · The paper itself

Abstract

Sulfonylureas are a cornerstone of type 2 diabetes therapy despite interindividual variability in response. Despite well-documented sex-based differences, pharmacogenomic and genome-wide association studies (GWAS) have largely overlooked sex as a biological variable. We conducted the first sex-stratified GWAS of hemoglobin A1c (HbA1c) response to sulfonylureas in Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial participants (N = 871). Variants meeting genome-wide (P < 5.0 × 10

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsSulfonylurea CompoundsAgedBlood GlucoseFemaleGenome-Wide Association StudyGlipizideGlycated HemoglobinHumansInsulinInsulin SecretagoguesMaleMetforminMiddle AgedPharmacogeneticsBlood GlucoseGlipizideGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinInsulin SecretagoguesMetforminSulfonylurea Compounds

Identifiers

PMID42504935
PMCPMC13403371

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.